ArticleVirology journal2025
Long-term persistence of serum IgM antibodies against chikungunya virus in patients with chronic arthralgia.
Article in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Evidence of Chikungunya Virus Reinfection in Two Patients With Lupus During the 2024-2025 Outbreak on Reunion Island.Open forum infectious diseases · 2026Article
- Correction: Long-term persistence of serum IgM antibodies against chikungunya virus in patients with chronic arthralgia.Virology journal · 2025Article
- Development of nanobody-based DAS-ELISA and Au nanoparticle-based immunochromatographic test strip for highly sensitive detection of Chikungunya virus.Frontiers in immunology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
Abstract
backgroundAnti-Chikungunya virus (CHIKV) IgM antibodies may persist for months after infection in some individuals, but the evidence is limited, and their exact duration remains unknown.
objectiveThis study aimed to determine the duration for which anti-CHIKV IgM antibodies remain detectable following acute infection.
methodsA commercial ELISA was used to assess the frequency of anti-CHIKV IgM antibody detection over time in 145 longitudinal serum samples obtained from 45 laboratory-confirmed chikungunya patients in Brazil (two to six samples per patient).
resultsAmong samples obtained within seven days post-symptom onset (DPSO), 13% (6/45) were IgM-positive. Between 10 and 120 DPSO, 100% (62/62) of samples were positive. Positivity rates for samples collected between 121 - 720, 721-900, 901-1,080, 1,081-1,260, and > 1,260 DPSO were 62% (5/8), 35% (6/17), 12% (1/8), 33% (1/3) and 50% (1/2), respectively. Notably, among 21 patients who developed chronic arthralgia and had at least one sample collected > 720 DPSO, 7 (33%) still had detectable anti-CHIKV IgM. This suggests that approximately one-third of chikungunya patients with chronic arthralgia may maintain anti-CHIKV IgM for over two years following acute disease.
conclusionsOur findings indicate that anti-CHIKV IgM antibodies can persist substantially longer than typically observed for acute RNA virus infections. This has significant implications for chikungunya diagnosis and surveillance. Further research is needed to determine whether long-term IgM persistence also occurs in patients without chronic chikungunya symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.